PeptiDream Inc. Company Profile

23:47 EDT 23rd June 2018 | BioPortfolio

PeptiDream Inc. is a public (Tokyo Stock Exchange Mothers 4587) biopharmaceutical company founded in 2006 employing our proprietary Peptide Discovery Platform System (PDPS), a state-of-the-art highly versatile peptide generation and selection platform which enables the production of highly diverse (trillions) non-standard peptide libraries with high efficiency, for the discovery and development of best-in-class and first-in-class peptide-based therapeutics. PeptiDream aspires to be a world leader in the discovery and development of novel highly functional peptide therapeutics to address unmet medical needs and improve the quality of life of patients worldwide. For further information please visit

News Articles [10 Associated News Articles listed on BioPortfolio]

PeptiDream Announces the Appointment of Dr. Kiyofumi Kaneshiro to the Management Team at PeptiDream Inc.

PeptiDream Inc., a Kanagawa-based biopharmaceutical company (“PeptiDream”)(TOKYO:4587) announced today, the appointment of Dr. Kiyofumi Kaneshiro to the management team at Pep...

Appointments: Hikma, Ipsen, PeptiDream, Targovax, Moderna and Perrigo

The latest biopharma industry appointments include C-suite hires at Hikma, Ipsen, Sinclair PeptiDream, Targovax, Nicox, Moderna, Antabio and Perrigo; as...   

Management tracks: Ipsen, PeptiDream

Sosei Collaboration with PeptiDream Progressing Well

TOKYO and LONDON, May 24, 2018 /PRNewswire/ -- Peptide antagonists with high affinity and selectivity against PAR2 target identified Sosei Group Corporation ("Sosei" or the "Company"; TSE Mothers ...

Should Celgene Succumb To The Charms Of Juno?

Observers are weighing up whether it makes sense for Celgene to spend in the region of $12bn and plump for...    

Asia Executives To Watch: GSK, Kyowa Hakko, PeptiDream

The coming of the new year has brought a flurry of executive changes. GSK Japan has a new president, Kyowa...   

Glenmark Progresses Novel Pain Asset With Partnering In Mind

Glenmark is moving ahead with studies for its inhibitor of mPGES-1 amid cautious optimism. Pain management is, however, not a...   

PeptiDream Inc 4587 Financial and Strategic SWOT Analysis Review [Report Updated: 09032018] Prices from USD $300

SummaryPeptiDream Inc PeptiDream is a biopharmaceutical company that discovers and develops constrained peptides, small molecule, and peptidedrug conjugate therapeutics. The company develops peptide d...

Drugs and Medications [0 Results]


PubMed Articles [0 Results]


Clinical Trials [0 Results]


Companies [1 Associated Companies listed on BioPortfolio]

PeptiDream Inc.

PeptiDream Inc. is a public (Tokyo Stock Exchange Mothers 4587) biopharmaceutical company founded in 2006 employing our proprietary Peptide Discovery Platform System (PDPS), a sta...

More Information about "PeptiDream Inc." on BioPortfolio

We have published hundreds of PeptiDream Inc. news stories on BioPortfolio along with dozens of PeptiDream Inc. Clinical Trials and PubMed Articles about PeptiDream Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of PeptiDream Inc. Companies in our database. You can also find out about relevant PeptiDream Inc. Drugs and Medications on this site too.

Quick Search


Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Corporate Database Quicklinks

Searches Linking to this Company Record